Neumora Therapeutics, Inc. NMRA 深 滬
等待開盤 10-03 09:30:00 美东时间
1.78
0.000
0.00%
華盛通- 最 高1.845
- 今 開1.79
- 成交量 52.82万股
- 最 低 1.70
- 昨 收 1.78
- 總市值 2.88亿
- 52周最高 17.1874
- 市盈率 靜 --
- 換手率 0.33%
- 52周最低 0.611
- 委 比 7.75%
- 總股本 1.62亿
- 歷史最高 21.00
- 量 比 1.32
- 振 幅 8.15%
- 歷史最低 0.611
- 每 手 1
- 風險率 4.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Neumora Therapeutics to Host Virtual R&D Day on October 27
Neumora Therapeutics will host a virtual R&D Day on October 27, 2025, to discuss its pipeline, including NMRA-215 (NLRP3 inhibitor for obesity), NMRA-511 (potential treatment for Alzheimer's disease agitation), its M4 franchise, and navacaprant (kappa opioid receptor antagonist in Phase 3). The event will provide updates on preclinical and clinical data, with registration available via the company's website.
10-01 11:00
JP Morgan Downgrades Neumora Therapeutics to Underweight
JP Morgan analyst Tessa Romero downgrades Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Underweight.
09-16 18:39
Neumora Therapeutics to Participate in Upcoming Conferences in September
Neumora Therapeutics will attend three investor conferences in September 2025 to discuss its seven therapeutic programs targeting underserved diseases. Management will participate in one-on-one meetings at the Wells Fargo Healthcare Conference on September 4 in Boston and the Morgan Stanley Global Healthcare Conference on September 8 in New York. They will also engage in a fireside chat at the H.C. Wainwright Global Investment Conference on Septe...
09-02 11:00
Neumora Therapeutics GAAP EPS of -$0.33
Neumora Therapeutics press release (NASDAQ:NMRA): Q2 GAAP EPS of -$0.33. Cash Position: As of June 30, 2025, Neumora had cash, cash equivalents and marketable securities of $217.6 million. Financial G...
08-07 05:53
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Neumora Therapeutics announced the initiation of a Phase 1 study for NMRA-861, a potential best-in-class M4 PAM for schizophrenia, with data expected in early 2026. The company prioritized obesity as the lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with preclinical data from diet-induced obesity (DIO) mouse models expected in 2025. Neumora anticipates six clinical data readouts over the next 18 months, including Phase 3...
08-06 20:05
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
<p>Neumora Therapeutics, Inc. announced it will host a conference call and live webcast on August 6, 2025, at 4:30 p.m. ET to discuss its second quarter 2025 financial results and provide a business update. The event will be available on the Company’s website at www.neumoratx.com, with a replay archived for 30 days. Participants can register here in advance. Neumora is a clinical-stage biopharmaceutical company focused on developing innovative th...
07-23 11:00
瑞穗：核心新药NMRA-861销售有望达12亿美元 上调Neumora(NMRA.US)目标价至5美元
瑞穗分析师Graig Suvannavejh发表研报，将Neumora Therapeutics目标价从4美元上调至5美元，并维持“跑赢大盘”评级。
07-21 14:35
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 90.1% to $2.3 during...
07-19 01:06
Mizuho Maintains Outperform on Neumora Therapeutics, Raises Price Target to $5
Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and raises the price target from $4 to $5.
07-16 20:19
